Drugs / Darbepoietin Alfa
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05810311 Comparator | Jun 2025 → Jan 2027 expected | diabetic kidney disease | Region Stockholm | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darbepoietin Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05810311 ↗ |
| Known as | Aranesp | “The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week.” NCT05810311 ↗ |
| Route | Subcutaneous | “The control group will receive darbepoietin alpha (Aranesp) s.c. 0.45mg/kg once a week.” NCT05810311 ↗ |